Business Context and Reporting Period
This Form 8-K filing by Aptevo Therapeutics Inc. (APVO) was submitted on April 7, 2022, reporting an event that occurred on April 1, 2022. The Company is a biopharmaceutical entity listed on The Nasdaq Capital Market.
Key Financial Metrics
The filing references the Company's annual report for the year ended December 31, 2021, which reported stockholders' equity of $1,216,000. This figure is below the Nasdaq Listing Rule 5550(b)(1) requirement of $2,500,000 in stockholders' equity for continued listing. The filing does not provide specific data regarding revenue, profit, cash flow, margins, or debt levels.
Material Changes
The primary material event is the receipt of a notification from The Nasdaq Stock Market LLC indicating non-compliance with the minimum stockholders' equity requirement. This deficiency is based on the financial position reported in the 2021 annual report.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has 45 calendar days (until May 16, 2022) to submit a plan to regain compliance. If accepted, the Company may be granted up to 180 calendar days from April 1, 2022, to evidence compliance.
- Current Status: The notification has no immediate impact on the listing; the common stock will continue to be listed and traded on Nasdaq pending compliance with other requirements.
- Risks: There is no assurance that the Company will be able to regain compliance or that its plan will be accepted. Failure to regain compliance could lead to delisting, though the Company retains the right to a hearing before an independent panel.
- Management Action: The Company intends to take all reasonable measures to resolve the deficiency and plans to submit a compliance plan by the deadline.
Investor Verification Checklist
- Verify the Company's current stockholders' equity and any capital raising activities undertaken since the 2021 annual report.
- Monitor the submission of the compliance plan to Nasdaq by the May 16, 2022 deadline.
- Review the Company's options for resolving the equity deficiency, such as equity offerings or other capital transactions.
- Check for any subsequent filings regarding the acceptance or rejection of the compliance plan by Nasdaq staff.